Business Context and Reporting Period
This Form 8-K is a current report filed by AntriaBio, Inc. (not Rezolute, Inc.) on November 22, 2013, covering events occurring between November 22, 2013, and December 19, 2013. The company is a Delaware corporation headquartered in Menlo Park, California, engaged in biotechnology. The filing discloses material agreements regarding financing, a triggering event related to debt obligations, changes in board leadership, and the termination of a prior investment banking agreement.
Key Financial Metrics and Obligations
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on specific events rather than a periodic financial report. However, it discloses the following financial obligations and potential liabilities:
- Outstanding Debt: As of February 6, 2013, $562,500 of principal balance remained on 2010 Convertible Notes (8% interest), payable on demand.
- Specific Demand: A holder demanded payment of $39,690.05 (principal, accrued interest, and fees) by December 19, 2013.
- Proposed Financing Targets: The company engaged a new placement agent to assist with a potential bridge note financing of up to $3,500,000 and a broader financing of up to $13,000,000.
- Compensation Obligations: If financings close, the company owes the placement agent a 10% cash fee, warrants equal to 15% of proceeds, and a 3% expense fee.
Material Changes and Events
- New Placement Agent Agreement: On December 13, 2013, the company entered an exclusive 18-month agreement with a new placement agent to secure debt or equity financing.
- Debt Default Risk: On November 22, 2013, the company received a demand notice for payment on 2010 Notes. The deadline was extended to December 19, 2013. The company requested the holder delay legal action pending new financing.
- Termination of Prior Agreement: On December 18, 2013, the company mutually terminated its Investment Banking Agreement with Ladenburg Thalmann & Co Inc. regarding a proposed public offering.
- Withdrawal of Registration: On December 19, 2013, the company filed a Form RW to withdraw its previously filed Form S-1 Registration Statement (File No. 333-191463).
- Board Leadership Change: Steve Howe resigned as Chairman of the Board on December 13, 2013. Nevan Elam, the CEO, was appointed as the new Chairman. Mr. Howe remains a board member.
Outlook, Risks, and Management Commentary
Outlook and Financing Strategy: Management is actively pursuing a bridge note financing or a larger equity/debt financing to address liquidity needs and satisfy outstanding note obligations. The company has secured an exclusive placement agent to facilitate these efforts.
Risks and Contingencies:
- Liquidity Risk: The company faces an immediate obligation to pay $39,690.05 to a note holder. Failure to pay may result in legal action.
- Financing Uncertainty: The filing explicitly states there can be no assurance that the transactions contemplated under the new Placement Agent Agreement will be consummated.
- Securities Registration: Any securities offered under the new agreements are unregistered and may not be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify whether the $39,690.05 demand on the 2010 Notes was satisfied by the December 19, 2013 deadline.
- Confirm if the company successfully closed the bridge note financing (up to $3.5M) or the larger financing (up to $13M) with the new placement agent.
- Review subsequent filings to determine if the company has filed a new registration statement to replace the withdrawn Form S-1.
- Assess the company's current cash position and ability to fund operations without the proposed financing.